Investors gave been rotating away from technology. Genmab is a biotech stock that has rallied into a buy zone amid sharp earnings growth.
Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we … [1013 chars]
Source: Investor’s Business Daily | Published: 2025-12-26T16:07:25Z
Credit: Investor’s Business Daily
